2nd Drug Development Forum

Join 300+ biotech executives for better collaboration, effective funding strategies & productive R&D

September 25-27, 2017 | Renaissance Boston Waterfront Hotel

FierceBiotech's 2017 Fierce 15 Announced Group

2017 Event Highlights

image 1
image 2
image 3
image 4
image 5
image 6
image 7
image 8
image 9
image 10
image 11
image 12
image 13
image 14
image 15

Past Featured Speakers

EDWARD KAYE  CEO SAREPTA THERAPEUTICS
EDWARD KAYE

CEO
SAREPTA THERAPEUTICS

RICHARD GREGORY  CSO IMMUNOGEN
RICHARD GREGORY

CSO
IMMUNOGEN

SARA NOCHUR  Senior Vice President, Regulatory Affairs ALNYLAM PHARMACEUTICALS
SARA NOCHUR

Senior Vice President, Regulatory Affairs
ALNYLAM PHARMACEUTICALS

ROB SCOTT  CMO ABBVIE
ROB SCOTT

CMO
ABBVIE

ROY BAYNES  Senior Vice President, Head of Clinical Development MERCK
ROY BAYNES

Senior Vice President, Head of Clinical Development, Chief Medical Officer
MERCK

ANGUS GRANT  Vice President, Regulatory Affairs, Finance CELGENE
ANGUS GRANT

Corporate Vice President, Business Development
CELGENE

BRYON WORNSON  Vice President, Global Health and Value PFIZER
BRYON WORNSON

Vice President, Global Health and Value
PFIZER

CHANDRA RAMANATHAN  Vice President and Head, East Coast Innovation Center BAYER
CHANDRA RAMANATHAN

Vice President and Head, East Coast Innovation Center
BAYER

JEREMY CHADWICK
JEREMY CHADWICK

Group Vice President Clinical Development Operations
SHIRE

GAIL CAWKWELL  CMO PURDUE PHARMACEUTICALS
GAIL CAWKWELL

CMO
PURDUE PHARMACEUTICALS

SHAKTI NARAYAN  Vice President, Head of Transactions JOHNSON & JOHNSON
SHAKTI NARAYAN

Vice President, Head of Transactions
JOHNSON & JOHNSON

Girish Aakalu
Girish Aakalu

Vice President and Head, Global Scientific Affairs and Scientific Exchange
IPSEN

Network with 300+ biotech leaders to set the best partnership and pipeline strategy

The biotech industry faces many serious strategic challenges with no obvious solutions.  The FDA approved only 22 new drug candidates in 2016 – less than half of the prior year, and the lowest level since 2010.  Meanwhile, the IPO market collapsed to its lowest level since 2009, and pressure from the government and payers is pushing pricing and value concerns into earlier stages of drug development.

Biopharma companies must increasingly adopt creative dealmaking, new digital technologies and early cost-effectiveness strategies, all while speeding up the R&D process.  This requires a novel way of thinking about partnerships and pipeline strategies, from the highest levels of biopharma leadership. 

The FierceBiotech 2nd Drug Development Forum draws together the industry’s executive decision-makers, to help guide your companies to success throughout the entire lifecycle – both for products and for companies themselves. 

Who Should Attend

This event is aimed at professionals in the pharmaceutical, biotech, medical device and venture capitalist fields responsible for:

  • Business Development
  • Corporate Development
  • Mergers and Acquisitions
  • Alliance Management
  • Partnering
  • Portfolio Management
  • Vendor Management
  • Licensing
  • Clinical Research/Clinical Development
  • Strategy/Product Strategy/Strategic Development
  • Clinical Trial Management
  • Data Management
  • Innovation
  • Investments
  • R&D
  • Regulatory Affairs
  • Patient/Medical Safety
  • Patient Centricity
  • Clinical Affairs/Operations
  • Regulatory Affairs/Compliance

This event is also of interest to:

  • CROs
  • Supply Chain Professionals
  • Law Firms
  • Clinical Data Management Specialists
  • Business Development Specialists
  • Legal

2017 SPONSORING ORGANIZATIONS